Standard BioTools Inc. (LAB)
NASDAQ: LAB · Real-Time Price · USD
0.6276
-0.0798 (-11.28%)
Nov 16, 2026, 1:23 PM EST - Market open
Standard BioTools Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 84.43 | 85.33 | 91.01 | 106.34 | 97.95 | 128.85 |
Other Revenue | - | - | - | - | - | 1.73 |
| 84.43 | 85.33 | 91.01 | 106.34 | 97.95 | 130.58 | |
Revenue Growth | -2.18% | -6.24% | -14.42% | 8.57% | -24.99% | -5.47% |
Cost of Revenue | 40.38 | 42.79 | 46.13 | 55.89 | 60.9 | 99.15 |
Gross Profit | 44.05 | 42.54 | 44.88 | 50.45 | 37.05 | 31.43 |
Selling, General & Admin | 77.18 | 109.86 | 103.06 | 87.54 | 102.29 | 98.89 |
Research & Development | 14.14 | 25.99 | 28.83 | 25.95 | 33.86 | - |
Operating Expenses | 91.32 | 135.85 | 131.89 | 113.49 | 136.14 | 98.89 |
Operating Income | -47.26 | -93.31 | -87.01 | -63.04 | -99.09 | -67.46 |
Interest Expense | -0.03 | -0.03 | -3.32 | -4.57 | -4.33 | -3.82 |
Interest & Investment Income | 14.69 | 9.18 | 20.2 | 5.57 | 2.23 | - |
Other Non Operating Income (Expenses) | 1.37 | 5 | -5.01 | 1.39 | -60.9 | 7.62 |
EBT Excluding Unusual Items | -31.23 | -79.16 | -75.13 | -60.64 | -162.09 | -63.66 |
Merger & Restructuring Charges | -35.03 | -16.94 | -40.48 | -13.56 | -13.59 | - |
Gain (Loss) on Sale of Investments | -3.37 | -0.6 | - | - | - | - |
Asset Writedown | - | - | - | - | -3.53 | - |
Other Unusual Items | -3.4 | - | 25.21 | - | -13.72 | - |
Pretax Income | -73.03 | -96.7 | -90.4 | -74.2 | -192.93 | -63.66 |
Income Tax Expense | -35.8 | -37.88 | 0.54 | 0.45 | -2.83 | -4.42 |
Earnings From Continuing Operations | -37.23 | -58.83 | -90.94 | -74.66 | -190.1 | -59.24 |
Earnings From Discontinued Operations | 170.3 | -16.07 | -47.95 | - | - | - |
Net Income | 133.08 | -74.9 | -138.89 | -74.66 | -190.1 | -59.24 |
Preferred Dividends & Other Adjustments | - | - | 46.01 | - | - | - |
Net Income to Common | 133.08 | -74.9 | -184.9 | -74.66 | -190.1 | -59.24 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 389 | 382 | 353 | 79 | 78 | 76 |
Shares Outstanding (Diluted) | 389 | 382 | 353 | 79 | 78 | 76 |
Shares Change | 2.75% | 8.03% | 346.24% | 1.09% | 3.32% | 5.19% |
EPS (Basic) | 0.34 | -0.20 | -0.52 | -0.94 | -2.43 | -0.78 |
EPS (Diluted) | 0.34 | -0.20 | -0.52 | -0.94 | -2.43 | -0.78 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | -65.65 | -82.65 | -151.81 | -46.12 | -93.2 | -57.33 |
Free Cash Flow Per Share | -0.17 | -0.22 | -0.43 | -0.58 | -1.19 | -0.76 |
Gross Margin | 52.18% | 49.86% | 49.32% | 47.44% | 37.83% | 24.07% |
Operating Margin | -55.98% | -109.34% | -95.60% | -59.28% | -101.17% | -51.66% |
Profit Margin | 157.62% | -87.77% | -203.17% | -70.20% | -194.08% | -45.36% |
Free Cash Flow Margin | -77.76% | -96.85% | -166.81% | -43.37% | -95.15% | -43.90% |
EBITDA | -38.09 | -82.33 | -70.15 | -47.86 | -84.06 | -63.81 |
EBITDA Margin | -45.12% | -96.48% | -77.08% | -45.01% | -85.82% | -48.86% |
D&A For EBITDA | 9.17 | 10.98 | 16.86 | 15.18 | 15.03 | 3.65 |
EBIT | -47.26 | -93.31 | -87.01 | -63.04 | -99.09 | -67.46 |
EBIT Margin | -55.98% | -109.34% | -95.60% | -59.28% | -101.17% | -51.66% |
Revenue as Reported | 84.43 | 85.33 | 91.01 | 106.34 | 97.95 | 130.58 |
Advertising Expenses | - | 2.2 | 2.6 | 2 | - | 3.4 |